The nation of Zimbabwe has declined a significant US health deal worth $367m (£272m) spanning five years because of the United States' insistence on sensitive biological samples.
This move became public after a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson later explained that the United States was demanding access to health data for research and commercial purposes but refused to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued dialogue to find a deal suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This rejection comes after a comparable situation in neighbouring Kenya, where a court halted a similar deal with the US following legal challenges were filed about the security of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
According to reports, Sixteen African countries have to date agreed to similar agreements, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our country would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our citizens should a future pandemic arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining frameworks previously established through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This framework is intended to ensure that when a country contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to continued discussions with our American counterparts on how subsequent co-operation could be designed in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body stated it recognised the official position, but suggested that negotiations must proceed given that much of the country's HIV programmes depended on foreign aid.
"Where specific concerns arise, including those relating to information security or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," the group said.
The situation emphasises the continuing challenges between receiving crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.